Oxaliplatin-5-fluorouracil and ionizing radiation: Importance of the sequence and influence of p53 status

Oncology

Volumn 64, Issue 3, 2003, Pages 280-287

  Magné, Nicolas ^a   Fischel, Jean Louis ^a   Formento, Patricia ^a   Etienne, Marie Christine ^a   Dubreuil, Alain ^a   Marcié, Serge ^a   Lagrange, Jean Léon ^a   Milano, Gérard ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

5 Fluorouracil; Colorectal cancer; In vitro experiments; Ionizing radiation; Oxaliplatin; Radiochemotherapy

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ARTICLE; CANCER CELL CULTURE; COLON CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; HUMAN; HUMAN CELL; IONIZING RADIATION; MATHEMATICAL COMPUTING; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIVITY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FLUOROURACIL; GAMMA RAYS; HUMANS; LEUCOVORIN; ORGANOPLATINUM COMPOUNDS; RADIOTHERAPY, ADJUVANT; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 0037262142     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000069308     Document Type: Article

References (35)

1. Quirke P, Durdey P, Dixon MF, Williams NS: Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumour spread and surgical excision. Lancet 1986;8514:996-999.
2. Heald RJ, Karanjia ND: Results of radical surgery for rectal cancer. World J Surg 1992;16: 848-857.
3. Fisher B, Wolmark N, Rockette H, et al: Postoperative adjuvant chemotherapy or adjuvant radiation therapy for rectal cancer. Results from NSABP R-01. J Natl Cancer Inst 1988;80:21-29.
4. O'Connell MJ, Martenson JA, Wieand HS, et al: Improving adjuvant therapy for rectal cancer by combining protracted infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994;331:502-507.
5. Malafosse R, Roger V, Nordlinger B: Sphincter-preserving surgery in patients with rectal cancer. Semin Oncol 2000;27:45-47.
6. Marsh PJ, James RD, Schofield PF: Adjuvant pre-operative radiotherapy for locally advanced rectal carcinoma: Results of a prospective randomized trial. Dis Colon Rectum 1994; 37:1205-1214.
7. Pahlman L, Glimelius B, Cedermark B, Lundell G, Rubio C, Rutqvist LE, et al: Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 1997;336:980-987.
8. Minsky B, Cohen A, Enker W, et al: Preoperative 5 fluorouracil, long-dose leucovorin and concurrent radiation therapy for rectal cancer. Cancer 1994;73:273-278.
9. Arnaud JP, Nordlinger B, Bosset JP, Boes GH, Sahmoud T, Schlag PM, et al: Radical surgery and post-operative radiotherapy as combined treatment in rectal cancer: Final results of a phase III study of the European Organization for Research and Treatment of Cancer. Br J Surg 1997;84:352-357.
10. Grann A, Feng C, Wong D, Saltz L, Paty PP, Guillem JG, Cohen AM, Minsky BD: Preoperative combined modality therapy for clinically resectable UT3 rectal adenocarcinoma. Int J Radiat Oncol Biol Phys 2001;49:987-995.
11. Sumpter K, Cunningham D: Combination chemotherapy and colorectal cancer. Semin Oncol 2000;27:105-111.
12. Becouarn Y, Ychou M, Ducreux M, et al: Phase II of oxaliplatin as first line chemotherapy in metastatic colorectal cancer patients. J Clin Oncol 1998;16:2739-2744.
13. Sobrero A, Kerr D, Glimelius B, Van Cutsem E, Milano G, Pritchard DM, Rougier P, Aapro M: New directions in the treatment of colorectal cancer: A look to the future. Eur J Cancer 2000;36:559-566.
14. Freyer G, Bossard N, Romestaing P, Mornex F, Chapet O, Trillet-Lenoir V, Gérard JP: Addition of oxaliplatin to continuous fluorouracil, L-folinic acid, and concomitant radiotherapy in rectal cancer: The Lyon R 97-03 phase I trial. J Clin Oncol 2001;19:2433-2438.
15. Li L, Story M, Legersky RJ: Cellular responses to ionizing radiation damage. Int J Radiat Oncol Biol Phys 2001;49:1157-1162.
16. Zellars RC, Naida JD, Davis MA, Lawrence TS: Effect of p53 overexpression on radiation sensitivity of human colon cancer cells. Radiat Oncol Invest 1997;5:43-49.
17. Wiggenraad R, Tamminga R, Blok P, Rouse R, Hermans J: The prognostic significance of p53 expression for survival and local control in rectal carcinoma treated with surgery and postoperative radiotherapy. Int J Radiat Oncol Biol Phys 1998;41:29-35.
18. Elsaleh H, Robbins P, Joseph D, Powell B, Grieu F, Menso L, Iacopetta B: Can p53 alterations be used to predict tumor response to pre-operative chemo-radiotherapy in locally advanced rectal cancer? Radiother Oncol 2000;56:239-244.
19. Adell G, Sun XF, Stal O, Klintenberg C, Sjödahl R, Nordenskjöld B: P53 status: An indicator for the effect of preoperative radiotherapy of rectal cancer. Radiother Oncol 1999;51:169-174.
20. Nehls O, Klump B, Holzmann K, Lammering G, Borchard F, Gruenagel HH, Gaco V, Gregor M, Porschen R: Influence of p53 status on prognosis in preoperatively irradiated rectal carcinoma. Cancer 1999;85:2541-2548.
21. Kones R: Folic acid: An update with new recommended daily allowances. South Med J 1990;83:1454-1458.
22. Carmichael J, De Graff WG, Gazdar AF, Minna JD, Mitchell JB: Evaluation of a tetrazolium-based semiautomated colorimetric assay: Assessment of chemosensitivity testing. Cancer Res 1987;47:936-940.
23. Steel G, Peckham MJ: Exploitable mechanisms in combined radiotherapy-chemotherapy: The concept of additivity. Int J Radiat Oncol Biol Phys 1979;5:85-93.
24. Kano Y, Ohnuma T, Okano T, Holland JF: Effects of vincristine in combination with methotrexate and other antitumor agents in human acute lymphoblastic leukemia cells in culture. Cancer Res 1988;48:351-356.
25. NIH Consensus Conference: Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990;264:1444-1450.
26. Rich T, Skibber J, Ajani J, et al: Preoperative infusional chemoradiation therapy for stage T3 rectal cancer. Int J Radiat Oncol Biol Phys 1995;32:1025-1029.
27. Meade P, Blatchford G, Thorson A, Christensen M, Ternet C: Preoperative chemoradiation downstages locally advanced ultrasound-staged rectal cancer. Am J Surg 1995;170:609-613.
28. McIlwrath AJ, Vasey PA, Ross GM, Brown R: Cell cycle arrests and radiosensitivity of human tumor cell lines: Dependence on wild-type p53 for radiosensitivity. Cancer Res 1994;54:3718-3722.
29. Brachman DG, Beckett M, Graves D, Haraf D, Vokes E, Weichselbaum RR: P53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer Res 1993;53:3667-3669.
30. Van Oijen MGCT, Slootweg PJ: Gain-of-function mutations in the tumor suppressor gene p53. Clin Cancer Res 2000;6:2138-2145.
31. Satyamoorthy K, Chehab NH, Waterman MJ, Lien MC, El-Deiry WS, Herlyn M, Halazonetis TD: Aberrant regulation and function of wild-type p53 in radioresistant melanoma cells. Cell Growth Differ 2000;11:467-474.
32. Vaganay-Juery S, Muller C, Marangoni E, Abdulkarim B, Deutsch E, Lambin P, Calsou P, Eschwege F, Salles B, Joiner M, Bourhis J: Decreased DNA-PK activity in human cancer cells exhibiting hypersensitivity to low-dose irradiation. Br J Cancer 2000;83:514-518.
33. Teyssier F, Bay JO, Dionet C, Verelle P: Cell cycle regulation after exposure to ionizing radiation. Bull Cancer 1999;86:345-357.
34. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB: Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 1992;89:7491-7495.
35. Bravard A, Luccioni C, Moustacchi E, Rigaud O: Contribution of antioxydant enzymes to the adaptive response to ionizing radiation of human lymphoblasts. Int J Radiat Biol 1999;75:639-645.